Study suggests RFA could be first-line treatment for early-stage HCC patients

Published date : 03 January 2012
Article date : 03 January 2012

Cool-tip ablation systemA study published in The American Journal of Gastroenterology suggests that radiofrequency ablation (RFA) might be a first-line treatment for selected patients with early-stage Hepatocellular Carcinoma.

The report from Japan found that one in four patients with hepatocellular carcinoma treated with percutaneous radiofrequency ablation was still alive ten years later. 

Dr Shuichiro Shiina and colleagues at the Graduate School of Medicine of the University of Tokyo concluded that "RFA could be locally curative, resulting in survival for as long as 10 years, and was a safe procedure. RFA might be a first-line treatment for selected patients with early-stage HCC."

The study looked at the Cool-tip ablation system manufactured by Covidien

The full report can be found here

Find out more about the Cool-tip ablation system here

Back to Listings

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.